A Pilot Study of Ipilimumab (MDX-CTLA4, MDX-010) in Lymphoma.
Phase of Trial: Phase I
Latest Information Update: 30 Sep 2016
At a glance
- Drugs Ipilimumab (Primary)
- Indications Colorectal cancer; Follicular lymphoma; Hodgkin's disease; Lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; Prostate cancer
- Focus Adverse reactions
- 27 Sep 2010 Actual end date changed from Feb 2010 to Sep 2010 as reported by ClinicalTrials.gov.
- 09 Mar 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 20 Oct 2008 'National Cancer Institute - Center for Cancer Research-Medical Oncology' added as sponsor as reported by ClinicalTrials.gov.